Article Text

Download PDFPDF

Case series of acute arthritis during COVID-19 admission
Free
  1. María-del-Carmen López-González1,
  2. Maria Luisa Peral-Garrido1,
  3. Irene Calabuig2,
  4. Ernesto Tovar-Sugrañes2,
  5. Vega Jovani3,
  6. Pilar Bernabeu2,
  7. Raquel García-Sevila4,
  8. Jose-Manuel León-Ramírez4,
  9. Oscar Moreno-Perez5,6,
  10. Vicente Boix6,7,
  11. Joan Gil4,
  12. Esperanza Merino7,
  13. Paloma Vela6,8,
  14. Mariano Andrés1,6
  1. 1 Seccion de Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain
  2. 2 Reumatología, Hospital General Universitario de Alicante, Alicante, Spain
  3. 3 Rheumatology, Hospital General de Alicante, Alicante, Spain
  4. 4 Neumología, Hospital General Universitario de Alicante, Alicante, Spain
  5. 5 Endocrinologia y Nutricion, Hospital General Universitario de Alicante, Alicante, Spain
  6. 6 Medicina Clínica, Universidad Miguel Hernandez de Elche, Elche, Spain
  7. 7 Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, Spain
  8. 8 Rheumatology Department, Hospital General Universitario de Alicante, Alicante, Spain
  1. Correspondence to Dr Mariano Andrés, Seccion de Reumatologia, Hospital General Universitario de Alicante, Alicante 03010, Spain; drmarianoandres{at}gmail.com

Statistics from Altmetric.com

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has changed life significantly worldwide. Rheumatologists also had to get used to the new context, prioritising remote over in-person consultations or solving doubts and giving advice to our immunocompromised patients. Besides, international collaborations have provided opinions concerning decisions that may affect people with rheumatic diseases; for instance, a major provision and use of hydroxychloroquine for COVID-19 might lead to a shortage for patients with lupus or rheumatoid arthritis, as Graef and colleagues point out in their recent viewpoint.1

In areas of higher impact of the outbreak, as occurred in Spain, some of us have collaborated with colleagues from respiratory medicine and infectious diseases within multidisciplinary teams to face COVID-19. A collateral advantage has been the opportunity to evaluate the musculoskeletal manifestations of COVID-19, to date just described as non-specific joint pain,2 while no cases of arthritis have been reported at diagnosis or during the infection.

Up to 30 April 2020, in Alicante General University Hospital, 306 patients with proven COVID-19 have been admitted. Eighty-one (26.4%) complained of muscle and joint pain at presentation. No patient had evident arthritis at admission, but four (1.3%) developed acute arthritis during hospitalisation. Here we present their relevant features (table 1).

Table 1

Clinical features and management of four patients with acute arthritis during COVID-19 admission

All patients had a history of recurrent acute arthritis in different locations (knee, first metatarsophalangeal joint or ankle). Three had a previous diagnosis of gout, but presence of crystals was only studied in one (patient 4). Treatment with allopurinol was variable, and none received daily colchicine.

COVID-19 was diagnosed in three of them by reverse transcriptase PCR (RT-PCR) for SARS-CoV-2 in nasopharyngeal aspirates. Patient 4 was repeatedly tested negative in RT-PCR but confirmed by SARS-CoV-2 IgM and IgG detection.3 All patients received hydroxychloroquine; tocilizumab (in three cases) and pulses of methylprednisolone (in two cases) were necessary because of severe pneumonia. Interestingly, all episodes of acute arthritis occurred despite those treatments. The synovial fluid analysis allowed definitive diagnoses, and flares successfully resolved with our standard approach (corticosteroids and colchicine).

Joint and muscle pain are common in acute viral illnesses. It also seems to occur in COVID-19,2 but the occurrence of arthritis has not been confirmed to date. Here we report four cases of acute arthritis developed during COVID-19 admissions, all due to crystal-proven flares (gout and calcium pyrophosphate disease). It remains essential to check every arthritis by polarised microscopy, even during the SARS-CoV-2 pandemic. Viral detection in synovial fluid had not been tested to date, though reported low rates of viraemia make it unlikely.4 5 We managed to have synovial fluids tested for SARS-CoV-2 by RT-PCR in the three cases, being all negative.

Rheumatologists, at multiple levels and from different perspectives,1 may be of great value during the COVID-19 pandemic.

References

Footnotes

  • Contributors All authors took part in data acquisition and analysis. MdCL-G and MA wrote the first draft. All authors approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MA declares speaking fees and research grants from Grunenthal, Menarini and Horizon.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles